Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks
- Sponsor
- University of Illinois at Chicago
- Study ID
- NCT01015495
- Phase
- PHASE1/PHASE2
- Status
- Withdrawn
Conditions
- Angioid Streaks
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- ranibizumab — DRUG0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
Study Details
The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.
Key Dates
- First listed
- Nov 18, 2009
- Start date
- Dec 31, 2009
- Status verified
- Jun 2012
- Primary completion
- Dec 31, 2010
- Completion
- Jan 31, 2011
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: ranibizumab
Primary Outcome Measure
The primary outcome measures for safety and tolerability are the following: • Incidence and severity of ocular adverse events, as identified by eye examination (including visual acuity testing) [ Time Frame: Month 12 ]